Paul Wren, Ph.D.


Chief Scientific Officer

Dr. Wren is a translational pharmacologist with a PhD from the University of Edinburgh. Most recently, Dr Wren was a Senior Director at GlaxoSmithKline (GSK) with a focus in Neuroscience R&D having previously worked for Sandoz (Novartis), Organon (Merck) and Pfizer across neurodegeneration, mood disorders and pain.

With experiences building teams in the UK, Italy, China and the US, Dr. Wren brings invaluable global neuroscience drug discovery and clinical development leadership expertise. He has served as a founding Executive Team Member of the MRC’s Dementias Platform UK and co-chair of the NIH’s Accelerating Medicines Partnership for Parkinson’s disease steering committee. Having initiated and led multiple neuroscience drug discovery efforts from conception to the clinic, Dr Wren’s appointment continues his focused passion to further therapeutic advances in genetically defined neurodegenerative diseases.